Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has entered into a strategic long-term manufacturing agreement with Samsung BioLogics for Tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

Filings for this novel investigational biologic has been accepted for review by the US Food and Drug Administration (USFDA) (May 2017) and the European Medicines Agency (EMA) (March 2017). The approximate value of the contract will be $55.5 million.

Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.